Personal tools

CL:0000134: Difference between revisions

From FANTOM5_SSTAR

Jump to: navigation, search
No edit summary
No edit summary
Line 1: Line 1:
{{CL
{{CL
|id=CL:0000134
|alt_id=CL:0002452
|name=mesenchymal cell
|namespace=cell
|def="A connective tissue cell that normally gives rise to other cells that are organized as three-dimensional masses. This cell type is CD73-positive, CD90-positive, CD105-positive, CD45-negative, CD34-negative, and MHCII-negative. They may further differentiate into osteoblasts, adipocytes, myocytes, neurons, or chondroblasts in vitro.  Originally described as residing in the bone marrow, this cell type is now known to reside in many, if not all, adult organs." [FB:ma, GOC:dsd, http://en.wikipedia.org/wiki/Mesenchymal_stem_cell, http://www.copewithcytokines.de/cope.cgi?key=mesenchymal%20stem%20cells, PMCID:PMC2613570, PMID:10102814j, PMID:16923606, PMID:17986482, PMID:19960544]
|xref=BTO:0002625;;BTO:0003298;;FMA:70546
|is_a=CL:0000048;;CL:0000219;;CL:0002320
|synonym="BMSC" EXACT [];;"bone marrow stromal cells" EXACT [];;"CFU-F" EXACT [];;"colony-forming unit-fibroblast" EXACT [];;"marrow stromal cells" EXACT [PMID:11378515];;"mesenchymal precursor cell" EXACT [];;"mesenchymal progenitor cells" EXACT [MESH:D044982];;"mesenchymal stem cell" EXACT [];;"mesenchymal stromal cell" EXACT [];;"mesenchymal stromal cells" EXACT [];;"MSC" EXACT [PMID:11378515];;"stem cells, mesenchymal" EXACT [MESH:D044982]
|comment=Many but not all mesenchymal cells derive from the mesoderm. MSCs are reportedly CD3-negative, CD4-negative, CD5-negative, CD8-negative, CD11a-negative, CD11b-negative, CD14-negative, CD19-negative, CD29-positive, CD31-negative, CD34-negative, CD38-negative, CD40-negative, CD44-positive, CD45-negative, CD49-positive, CD54-positive,  CD66b-negative, CD79a-negative, CD80-negative, CD102-positive, CD106-positive, CD117-positive, CD121a-positive, CD121b-positive, CD123-positive, CD124-positive, CD133-negative, CD146-positive, CD166-positive, CD271-positive, B220-negative, Gr1-negative, MHCI-positive, MHCII-negative, SSEA4-negative, sca1-positive, Ter119-negative, and glycophorin A-negative. Cultured MSCs are capable of producing stem cell factor, IL7, IL8, IL11, TGF-beta, cofilin, galectin-1, laminin-receptor 1, cyclophilin A, and MMP-2.
|comment=Many but not all mesenchymal cells derive from the mesoderm. MSCs are reportedly CD3-negative, CD4-negative, CD5-negative, CD8-negative, CD11a-negative, CD11b-negative, CD14-negative, CD19-negative, CD29-positive, CD31-negative, CD34-negative, CD38-negative, CD40-negative, CD44-positive, CD45-negative, CD49-positive, CD54-positive,  CD66b-negative, CD79a-negative, CD80-negative, CD102-positive, CD106-positive, CD117-positive, CD121a-positive, CD121b-positive, CD123-positive, CD124-positive, CD133-negative, CD146-positive, CD166-positive, CD271-positive, B220-negative, Gr1-negative, MHCI-positive, MHCII-negative, SSEA4-negative, sca1-positive, Ter119-negative, and glycophorin A-negative. Cultured MSCs are capable of producing stem cell factor, IL7, IL8, IL11, TGF-beta, cofilin, galectin-1, laminin-receptor 1, cyclophilin A, and MMP-2.
|alt_id=CL:0002452
|disjoint_from=
|union_of=
|created_by=
|created_by=
|obo_creation_date=
|def="A connective tissue cell that normally gives rise to other cells that are organized as three-dimensional masses. This cell type is CD73-positive, CD90-positive, CD105-positive, CD45-negative, CD34-negative, and MHCII-negative. They may further differentiate into osteoblasts, adipocytes, myocytes, neurons, or chondroblasts in vitro.  Originally described as residing in the bone marrow, this cell type is now known to reside in many, if not all, adult organs." [FB:ma, GOC:dsd, http://en.wikipedia.org/wiki/Mesenchymal_stem_cell, http://www.copewithcytokines.de/cope.cgi?key
|subset=
|derives_from=
|derives_from=
|develops_from=
|develops_from=
|disjoint_from=
|has_quality=
|has_quality=
|id=CL:0000134
|is_a=CL:0000048 ;;CL:0000219 ;;CL:0002320
|is_obsolete=
|located_in=
|located_in=
|name=mesenchymal cell
|namespace=cell
|obo_creation_date=
|part_of=
|part_of=
|preceded_by=
|property_value=IAO:0000412 http://purl.obolibrary.org/obo/cl.owl
|property_value=IAO:0000412 http://purl.obolibrary.org/obo/cl.owl
|is_obsolete=
|subset=
|preceded_by=
|synonym="BMSC" EXACT [];;"bone marrow stromal cells" EXACT [];;"CFU-F" EXACT [];;"colony-forming unit-fibroblast" EXACT [];;"marrow stromal cells" EXACT [PMID:11378515];;"mesenchymal precursor cell" EXACT [];;"mesenchymal progenitor cells" EXACT [MESH:D044982];;"mesenchymal stem cell" EXACT [];;"mesenchymal stromal cell" EXACT [];;"mesenchymal stromal cells" EXACT [];;"MSC" EXACT [PMID:11378515];;"stem cells, mesenchymal" EXACT [MESH:D044982]
|union_of=
|xref=BTO:0002625;;BTO:0003298;;FMA:70546
}}
}}

Revision as of 10:14, 12 September 2014

Name:mesenchymal cell
Namespace:cell
Definition:"A connective tissue cell that normally gives rise to other cells that are organized as three-dimensional masses. This cell type is CD73-positive, CD90-positive, CD105-positive, CD45-negative, CD34-negative, and MHCII-negative. They may further differentiate into osteoblasts, adipocytes, myocytes, neurons, or chondroblasts in vitro. Originally described as residing in the bone marrow, this cell type is now known to reside in many, if not all, adult organs." [FB:ma, GOC:dsd, http://en.wikipedia.org/wiki/Mesenchymal_stem_cell, http://www.copewithcytokines.de/cope.cgi?key
Xrefs:
links:

BTO:0002625
BTO:0003298

FMA:70546
Synonyms: "BMSC" EXACT []
"bone marrow stromal cells" EXACT []
"CFU-F" EXACT []
"colony-forming unit-fibroblast" EXACT []
"marrow stromal cells" EXACT [PMID:11378515]
"mesenchymal precursor cell" EXACT []
"mesenchymal progenitor cells" EXACT [MESH:D044982]
"mesenchymal stem cell" EXACT []
"mesenchymal stromal cell" EXACT []
"mesenchymal stromal cells" EXACT []
"MSC" EXACT [PMID:11378515]
"stem cells, mesenchymal" EXACT [MESH:D044982]
Comments:Many but not all mesenchymal cells derive from the mesoderm. MSCs are reportedly CD3-negative, CD4-negative, CD5-negative, CD8-negative, CD11a-negative, CD11b-negative, CD14-negative, CD19-negative, CD29-positive, CD31-negative, CD34-negative, CD38-negative, CD40-negative, CD44-positive, CD45-negative, CD49-positive, CD54-positive, CD66b-negative, CD79a-negative, CD80-negative, CD102-positive, CD106-positive, CD117-positive, CD121a-positive, CD121b-positive, CD123-positive, CD124-positive, CD133-negative, CD146-positive, CD166-positive, CD271-positive, B220-negative, Gr1-negative, MHCI-positive, MHCII-negative, SSEA4-negative, sca1-positive, Ter119-negative, and glycophorin A-negative. Cultured MSCs are capable of producing stem cell factor, IL7, IL8, IL11, TGF-beta, cofilin, galectin-1, laminin-receptor 1, cyclophilin A, and MMP-2.
Alt_id: CL:0002452


Ontology association <br>Each term has an is_a parent in the Cell ontology, which has a linkage to an another entity and FANTOM5 samples.Libraries were grouped into mutually exclusive facets according to the FANTOM5 sample ontology mapping to Cell ontologies.<br><br>link to ontology dataset<br>data

Parents

is_a:CL:0000048(multi fate stem cell),CL:0000219(motile cell),CL:0002320(connective tissue cell)



Children


is a:CL:0000335 (mesenchyme condensation cell),CL:0000346 (hair follicle dermal papilla cell),CL:0000566 (angioblastic mesenchymal cell),CL:0000569 (cardiac mesenchymal cell),CL:0002537 (amnion mesenchymal stem cell),CL:0002540 (mesenchymal stem cell of the bone marrow),CL:0002541 (chorionic membrane mesenchymal stem cell),CL:0002569 (mesenchymal stem cell of umbilical cord),CL:0002570 (mesenchymal stem cell of adipose),CL:0002571 (hepatic mesenchymal stem cell),CL:0002572 (vertebral mesenchymal stem cell),FF:10447-106F6 (),FF:10568-108B1 (mesenchymal stem cell line:Hu5/E18),FF:10813-111B3 (normal embryonic palatal mesenchymal cell line:HEPM)
derives from:FF:0000272 (human ovarian cancer mesenchymal precursor cell sample),FF:0000404 (mouse mesenchymal stem cell line: ST2 sample)
develops from:CL:0000057 (fibroblast),CL:0000136 (fat cell),CL:0000214 (synovial cell),CL:0000499 (stromal cell),CL:0000566 (angioblastic mesenchymal cell),CL:0000650 (mesangial cell)

Ontology Tree: Loaded from BioPortal

Ontorolgy tree(Small window open)


FF samples<br>It includes FANTOM5 samples that overlay the Cell ontology.

Human (Homo sapiens)

... further results Mouse (Mus musculus)

... further results


Enrichment analysis: top 100 FFCP enriched with this ontology termTOP 100 FANTOM5 Cage Peaks enriched with CL:0000134 (mesenchymal cell), sorted by p-values <br>Analyst: Hideya Kawaji<br><br>link to source dataset <br>human : data <br>mouse : data

P-valueFFCPShort description
7.06e-46FFCP PHASE1:Hg19::chr18:18691563..18691610,-#_42e99399a72aa33e94ff88258e1c9e6cp4@ROCK1
7.06e-46FFCP PHASE2:Hg19::chr18:18691563..18691610,-#_42e99399a72aa33e94ff88258e1c9e6cp4@ROCK1
1.52e-44FFCP PHASE2:Hg19::chr2:182322231..182322262,+#_62be04799ba177e90f8f5d92770b751fp2@ITGA4
1.52e-44FFCP PHASE1:Hg19::chr2:182322231..182322262,+#_62be04799ba177e90f8f5d92770b751fp2@ITGA4
3.1e-43FFCP PHASE1:Hg19::chr19:48828606..48828637,+#_3bb74022b765c1f33e5dc8781302c2afp2@EMP3
3.1e-43FFCP PHASE2:Hg19::chr19:48828606..48828637,+#_3bb74022b765c1f33e5dc8781302c2afp2@EMP3
2.35e-41FFCP PHASE1:Hg19::chr2:74781828..74781898,+#_bf8451a0a3ec37c23751eb6f1f4192b6p1@DOK1
2.35e-41FFCP PHASE2:Hg19::chr2:74781828..74781898,+#_bf8451a0a3ec37c23751eb6f1f4192b6p1@DOK1
9.88e-41FFCP PHASE2:Hg19::chr5:78281092..78281154,-#_c98ed36561133786f7d3944871d57b5cp1@ARSB
9.88e-41FFCP PHASE1:Hg19::chr5:78281092..78281154,-#_c98ed36561133786f7d3944871d57b5cp1@ARSB
7.26e-40FFCP PHASE2:Hg19::chr16:50300440..50300485,+#_24f4b7ae117d1c3a71dcd6fbd70234cdp1@ADCY7
7.26e-40FFCP PHASE1:Hg19::chr16:50300440..50300485,+#_24f4b7ae117d1c3a71dcd6fbd70234cdp1@ADCY7
4.19e-39FFCP PHASE2:Hg19::chr6:31704075..31704106,-#_dfe511a14ab6bec2a06bd90c71a704cap2@CLIC1
4.19e-39FFCP PHASE1:Hg19::chr6:31704075..31704106,-#_dfe511a14ab6bec2a06bd90c71a704cap2@CLIC1
5.06e-39FFCP PHASE1:Hg19::chr15:73076030..73076121,-#_0d101cc435d073e3d6f2ac3ed178359ep1@ADPGK
5.06e-39FFCP PHASE2:Hg19::chr15:73076030..73076121,-#_0d101cc435d073e3d6f2ac3ed178359ep1@ADPGK
4.24e-37FFCP PHASE1:Hg19::chr2:114647617..114647739,+#_229c77c516173e53b2796e054d4b439ap1@ACTR3
4.24e-37FFCP PHASE2:Hg19::chr2:114647617..114647739,+#_229c77c516173e53b2796e054d4b439ap1@ACTR3
1.73e-36FFCP PHASE1:Hg19::chr1:153518270..153518290,-#_757519cb7d16d962057ff8e1b691d5ebp1@S100A4
1.73e-36FFCP PHASE2:Hg19::chr1:153518270..153518290,-#_757519cb7d16d962057ff8e1b691d5ebp1@S100A4
2.86e-36FFCP PHASE2:Mm9::chr7:26474167..26474188,-#_495c3b2202c840aa099201d2d459268fp@chr7:26474167..26474188, -
2.86e-36FFCP PHASE1:Mm9::chr7:26474167..26474188,-#_495c3b2202c840aa099201d2d459268fp@chr7:26474167..26474188, -
4.65e-36FFCP PHASE2:Hg19::chr13:41635029..41635044,-#_d8b228c17fce3f6fe72bf9a4e81c0e8fp4@ELF1
4.65e-36FFCP PHASE1:Hg19::chr13:41635029..41635044,-#_d8b228c17fce3f6fe72bf9a4e81c0e8fp4@ELF1
5.33e-36FFCP PHASE1:Hg19::chr12:44152740..44152815,+#_77a647aa5f3bb143b0cd13fcc6cff2d2p1@IRAK4
5.33e-36FFCP PHASE2:Hg19::chr12:44152740..44152815,+#_77a647aa5f3bb143b0cd13fcc6cff2d2p1@IRAK4
5.97e-36FFCP PHASE2:Hg19::chrX:117629766..117629846,+#_ea3f0025a53b79f187453c9d6f44d7d5p1@DOCK11
5.97e-36FFCP PHASE1:Hg19::chrX:117629766..117629846,+#_ea3f0025a53b79f187453c9d6f44d7d5p1@DOCK11
1.13e-35FFCP PHASE1:Hg19::chr2:182322070..182322155,+#_25da9dc1465729ef77bd17853abc918cp1@ITGA4
1.13e-35FFCP PHASE2:Hg19::chr2:182322070..182322155,+#_25da9dc1465729ef77bd17853abc918cp1@ITGA4
1.63e-35FFCP PHASE1:Hg19::chr10:26727647..26727722,+#_cea1a987c4bf237744859df942a36a83p2@APBB1IP
1.63e-35FFCP PHASE2:Hg19::chr10:26727647..26727722,+#_cea1a987c4bf237744859df942a36a83p2@APBB1IP
3.89e-35FFCP PHASE2:Hg19::chr2:197036289..197036314,-#_dcc3a8acf877df704111fdd0d66cc52bp1@STK17B
3.89e-35FFCP PHASE1:Hg19::chr2:197036289..197036314,-#_dcc3a8acf877df704111fdd0d66cc52bp1@STK17B
3.91e-35FFCP PHASE2:Hg19::chr19:48828647..48828658,+#_1dd0f2b58191b0d66a7cdda11eeff19ep3@EMP3
3.91e-35FFCP PHASE1:Hg19::chr19:48828647..48828658,+#_1dd0f2b58191b0d66a7cdda11eeff19ep3@EMP3
8.17e-35FFCP PHASE2:Hg19::chr3:5229382..5229408,+#_ea6f273909fee2203f11490130dce1e3p1@EDEM1
8.17e-35FFCP PHASE1:Hg19::chr3:5229382..5229408,+#_ea6f273909fee2203f11490130dce1e3p1@EDEM1
2.39e-34FFCP PHASE1:Hg19::chrX:19905661..19905699,-#_e1f2535d9637712a1cbc555366d52e46p1@SH3KBP1
2.39e-34FFCP PHASE2:Hg19::chrX:19905661..19905699,-#_e1f2535d9637712a1cbc555366d52e46p1@SH3KBP1
3.31e-34FFCP PHASE2:Hg19::chr17:56415424..56415454,-#_b38f470c12d265250e2450bc90995f5cp@chr17:56415424..56415454, -
3.31e-34FFCP PHASE1:Hg19::chr17:56415424..56415454,-#_b38f470c12d265250e2450bc90995f5cp@chr17:56415424..56415454, -
4.02e-34FFCP PHASE2:Hg19::chr1:145096480..145096513,+#_7d7be057434fadc8f92b03a97d29db19p2@SEC22B
4.02e-34FFCP PHASE1:Hg19::chr1:145096480..145096513,+#_7d7be057434fadc8f92b03a97d29db19p2@SEC22B
4.3e-34FFCP PHASE1:Hg19::chr2:68592394..68592405,+#_414c5c54e132a49335476d4933f8ae59p2@PLEK
4.3e-34FFCP PHASE2:Hg19::chr2:68592394..68592405,+#_414c5c54e132a49335476d4933f8ae59p2@PLEK
4.87e-34FFCP PHASE2:Hg19::chr2:197036269..197036287,-#_264daf92cfd029608826bb70df05658dp2@STK17B
4.87e-34FFCP PHASE1:Hg19::chr2:197036269..197036287,-#_264daf92cfd029608826bb70df05658dp2@STK17B
9.77e-34FFCP PHASE1:Hg19::chr12:123920991..123921047,-#_83756ed1d0cf5a573a88e4d8449a04b9p1@RILPL2
9.77e-34FFCP PHASE2:Hg19::chr12:123920991..123921047,-#_83756ed1d0cf5a573a88e4d8449a04b9p1@RILPL2
1.03e-33FFCP PHASE2:Hg19::chr3:50378235..50378286,-#_d5538e3b6270fd2e406f866c4c805361p2@RASSF1
1.03e-33FFCP PHASE1:Hg19::chr3:50378235..50378286,-#_d5538e3b6270fd2e406f866c4c805361p2@RASSF1
1.83e-33FFCP PHASE2:Hg19::chr13:41593405..41593416,-#_fd0b27acb6a71fddb3c2612b0bebbb94p9@ELF1
1.83e-33FFCP PHASE1:Hg19::chr13:41593405..41593416,-#_fd0b27acb6a71fddb3c2612b0bebbb94p9@ELF1
2.8e-33FFCP PHASE1:Hg19::chr2:192542577..192542595,-#_cc9c5066883ac4f974dc8ec7f5f68cd3p@chr2:192542577..192542595, -
2.8e-33FFCP PHASE2:Hg19::chr2:192542577..192542595,-#_cc9c5066883ac4f974dc8ec7f5f68cd3p@chr2:192542577..192542595, -
5.24e-33FFCP PHASE2:Mm9::chr4:140255879..140255890,+#_cb5449e578982fc76462eed76139a661p@chr4:140255879..140255890, +
5.24e-33FFCP PHASE1:Mm9::chr4:140255879..140255890,+#_cb5449e578982fc76462eed76139a661p@chr4:140255879..140255890, +
2.97e-32FFCP PHASE2:Hg19::chr4:80994619..80994633,-#_bd381afefba4ce607b0856096a9ad001p6@ANTXR2
2.97e-32FFCP PHASE1:Hg19::chr4:80994619..80994633,-#_bd381afefba4ce607b0856096a9ad001p6@ANTXR2
3.78e-32FFCP PHASE2:Hg19::chr2:182322344..182322359,+#_4cee93ae4179d6c4793727f30ba72c6fp6@ITGA4
3.78e-32FFCP PHASE1:Hg19::chr2:182322344..182322359,+#_4cee93ae4179d6c4793727f30ba72c6fp6@ITGA4
8.65e-32FFCP PHASE1:Hg19::chr10:98480301..98480315,-#_5e2b350bba6d35f6ac0ff08007f3221ap3@PIK3AP1
8.65e-32FFCP PHASE2:Hg19::chr10:98480301..98480315,-#_5e2b350bba6d35f6ac0ff08007f3221ap3@PIK3AP1
9.23e-32FFCP PHASE2:Hg19::chr18:3449527..3449582,+#_ec54150f0347fa1764b02aeba9fff61dp6@TGIF1
9.23e-32FFCP PHASE1:Hg19::chr18:3449527..3449582,+#_ec54150f0347fa1764b02aeba9fff61dp6@TGIF1
9.26e-32FFCP PHASE1:Hg19::chr19:48828539..48828550,+#_b22f81ed12276c5278a3a57f361cd60bp4@EMP3
9.26e-32FFCP PHASE2:Hg19::chr19:48828539..48828550,+#_b22f81ed12276c5278a3a57f361cd60bp4@EMP3
1.1e-31FFCP PHASE1:Hg19::chr20:61584026..61584096,+#_f4c66e71fa4056d2404cfdec86982963p1@SLC17A9
1.1e-31FFCP PHASE2:Hg19::chr20:61584026..61584096,+#_f4c66e71fa4056d2404cfdec86982963p1@SLC17A9
1.1e-31FFCP PHASE2:Hg19::chr10:18948026..18948051,-#_f4c66e71fa4056d2404cfdec86982963p1@BC033534
1.1e-31FFCP PHASE1:Hg19::chr10:18948026..18948051,-#_f4c66e71fa4056d2404cfdec86982963p1@BC033534
1.76e-31FFCP PHASE1:Mm9::chr1:175560978..175561013,+#_8cef65a9d5947d6d7aea73a9c275db0ep1@Pyhin1
1.76e-31FFCP PHASE2:Mm9::chr1:175560978..175561013,+#_8cef65a9d5947d6d7aea73a9c275db0ep1@Pyhin1
2.76e-31FFCP PHASE1:Hg19::chr13:41593392..41593403,-#_1da1709fb93954dc65e054a958d5c389p7@ELF1
2.76e-31FFCP PHASE2:Hg19::chr13:41593392..41593403,-#_1da1709fb93954dc65e054a958d5c389p7@ELF1
4.86e-31FFCP PHASE1:Hg19::chr3:15837528..15837578,-#_e9c7532be4358ab112d7e25b1b73fd3fp@chr3:15837528..15837578, -
4.86e-31FFCP PHASE2:Hg19::chr3:15837528..15837578,-#_e9c7532be4358ab112d7e25b1b73fd3fp@chr3:15837528..15837578, -
5.26e-31FFCP PHASE1:Hg19::chr5:169724839..169724855,-#_f7227e4ccbbd63d6401a1fcb2ddd9831p3@LCP2
5.26e-31FFCP PHASE2:Hg19::chr5:169724839..169724855,-#_f7227e4ccbbd63d6401a1fcb2ddd9831p3@LCP2
5.28e-31FFCP PHASE1:Hg19::chr1:206730535..206730549,+#_5d5fe95965577dd07cefae338da5b8aep4@RASSF5
5.28e-31FFCP PHASE2:Hg19::chr1:206730535..206730549,+#_5d5fe95965577dd07cefae338da5b8aep4@RASSF5
6.88e-31FFCP PHASE1:Mm9::chr3:60407657..60407673,+#_5b68386c3c684f052c4d775ad94ff154p@chr3:60407657..60407673, +
6.88e-31FFCP PHASE2:Mm9::chr3:60407657..60407673,+#_5b68386c3c684f052c4d775ad94ff154p@chr3:60407657..60407673, +
9.92e-31FFCP PHASE2:Hg19::chr11:58343319..58343338,-#_577ef88db3331596929b2699c8157636p1@LPXN
9.92e-31FFCP PHASE1:Hg19::chr11:58343319..58343338,-#_577ef88db3331596929b2699c8157636p1@LPXN
9.98e-31FFCP PHASE2:Hg19::chr17:16319083..16319126,+#_9e667f3f2d2984a4f383277bc52bdc08p2@TRPV2
9.98e-31FFCP PHASE1:Hg19::chr17:16319083..16319126,+#_9e667f3f2d2984a4f383277bc52bdc08p2@TRPV2
1.64e-30FFCP PHASE2:Hg19::chr2:182322864..182322885,+#_670be93a162eee86edfc1437df5566a8p3@ITGA4
1.64e-30FFCP PHASE1:Hg19::chr2:182322864..182322885,+#_670be93a162eee86edfc1437df5566a8p3@ITGA4
1.65e-30FFCP PHASE2:Hg19::chr2:24149046..24149063,+#_376bbcb3dd002ba90e11011a0a4a92bep@chr2:24149046..24149063, +
1.65e-30FFCP PHASE1:Hg19::chr2:24149046..24149063,+#_376bbcb3dd002ba90e11011a0a4a92bep@chr2:24149046..24149063, +
2.02e-30FFCP PHASE2:Hg19::chr17:16319065..16319082,+#_362a582dd8919cb3ebadfa8ce24082cdp4@TRPV2
2.02e-30FFCP PHASE1:Hg19::chr17:16319065..16319082,+#_362a582dd8919cb3ebadfa8ce24082cdp4@TRPV2
2.42e-30FFCP PHASE2:Hg19::chr13:100153737..100153785,+#_b9c729de2ce7c96f9e68b9fe10b19709p1@TM9SF2
2.42e-30FFCP PHASE1:Hg19::chr13:100153737..100153785,+#_b9c729de2ce7c96f9e68b9fe10b19709p1@TM9SF2
2.93e-30FFCP PHASE2:Hg19::chr14:95982953..95982999,-#_0110da1ccdfd2989a9a2dda4b998a031p@chr14:95982953..95982999, -
2.93e-30FFCP PHASE1:Hg19::chr14:95982953..95982999,-#_0110da1ccdfd2989a9a2dda4b998a031p@chr14:95982953..95982999, -
4.67e-30FFCP PHASE1:Mm9::chr17:84587077..84587097,-#_85e7956fc4b12b6c9d756d95a0710e00p4@Zfp36l2
4.67e-30FFCP PHASE2:Mm9::chr17:84587077..84587097,-#_85e7956fc4b12b6c9d756d95a0710e00p4@Zfp36l2

Retrieved from "http://f5-webapp4.gsc.riken.jp/resource_browser/index.php?title=CL:0000134&oldid=3271867"